JAK1/2/3/TYK2

Class

JAK inhibitor

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are enzymes that sit just inside the cell membrane, attached to receptors for cytokines—signaling proteins that coordinate immune and blood cell activity. When a cytokine binds its receptor, paired JAKs activate one another and then add phosphate groups to STAT proteins, which travel to the nucleus and switch on genes involved in inflammation, cell proliferation, and immune cell development. Different cytokines rely on different JAK pairings, so a compound that inhibits all four family members interrupts a broad swath of this signaling network rather than a single cytokine's pathway. This breadth is useful because many inflammatory and autoimmune diseases, as well as certain blood cancers, are driven by more than one overactive cytokine pathway simultaneously. By dampening JAK-STAT signaling broadly, such inhibitors can reduce inflammatory cell recruitment, suppress abnormal proliferation of blood cell precursors, or blunt autoimmune tissue damage. The trade-off is that JAK signaling also supports normal immune surveillance and healthy blood cell production, so broad inhibition carries a mechanistic risk of increased susceptibility to infection and effects on red and white blood cell counts. This mechanism broadly matters across chronic inflammatory skin and joint diseases, certain bone marrow disorders, and other conditions where cytokine signaling is chronically dysregulated.